



**Minutes of the MLSC Investment Committee Meeting
April 15, 2026
Virtual Meeting**

DATE: April 15, 2026
TIME: 2:00 p.m. EST
PLACE: MLSC 1075 Main Street, Suite 100, Waltham, MA

Members Present: Julie Chen, Ph.D, Designee for UMass President Marty Meehan
Pam Randhawa
Brian Johnson
Bran Shim
Dana Mendhenhall

Members Absent:

Call to Order

The meeting was called to order and Dr. Kirk Taylor, CEO and President of the MLSC welcomed the committee members.

Approval of Meeting Minutes

Allyson McLaughlin Huntington, General Counsel and Board Secretary

Ms. Huntington presented the March 11, 2026 meeting minutes to the Committee for approval. Upon motion duly made and seconded a roll call of Committee members was taken and the Motion to approve the minutes carried.

2035 Fund Awards

Carla Reimold, PhD, EVP Scientific Innovation and Strategic Investments, provided a recap overview of the 2035 Fund and allocations for the programs in the tracks of the 2035 Fund, and introduced the three program tracks before the Committee. The Committee asked questions about the highlight summary of each program, and after brief discussion the Program Managers were introduced.

2026 Bits to Bytes

Audrey Byrne, PhD., Program Manager, Scientific Innovation and Strategic Investments, presented an overview of the application, review and selection process that is common to all three of the themed capital grant programs. Dr. Byrne provided details on the Bits to Bytes program, including the D.A.T.A. repository and the impact of the program. Dr. Byrne explained certain metrics that can be captured, including users who access the data sets that are in the D.A.T.A. repository, and the aggregate data on return on investment from the first years of the program. The committee members had some follow-up questions about D.A.T.A. and access to the data sets. Dr. Byrne detailed the applications for the Bits to Bytes program that were recommended for funding by the independent review panel. Dr. Byrne asked the committee to endorse bringing the 4 awards in the amount of \$3,268,540 forward to the April 29, 2026 Board of Directors Meeting.

The Investment Committee supported bringing this investment opportunity to the full Board of Directors at the April board meeting.

2026 Novel Therapeutics Delivery

Audrey Byrne, Ph.D., Program Manager, Scientific Innovation and Strategic Investments Dr. Byrne presented the Novel Therapeutics Delivery capital grant program, giving an overview of the program goals and requirements. Dr. Byrne provided the committee with seven applicants, providing a brief summary of the projects included in the applicant pool. Dr. Byrne gave detailed information on the proposed awardees as selected by the independent review panel. After fielding questions from

the committee members.

The Investment Committee supported bringing this investment opportunity to the full Board of Directors at the April board meeting.

2026 Women's Health Collaboration

Audrey Byrne, Ph.D., Program Manager, Scientific Innovation and Strategic Investments, presented the Women's Health Collaboration program, beginning with a general overview of the program goals and impact. Dr. Byrne gave an overview of the applications received in this round and the project recommended for funding by the independent review panel. Dr. Byrne provided the Committee with the opportunity to pose questions, concluding with the request to endorse the one award in the amount of \$1,500,000 to be brought forward to the April 29, 2026, Board of Directors Meeting.

The Investment Committee supported bringing this investment opportunity to the full Board of Directors at the April board meeting.

Other Business:

Adjourn

Materials Used During Meeting:

Agenda

Minutes of the March 11, 2026 Investment Committee Meeting

FY26 Accelerating Research Through Collaboration Awards Presentation